Exact Sciences/$EXAS
14:30
15:25
16:15
17:10
18:00
1D1W1MYTD1Y5YMAX
About Exact Sciences
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Ticker
$EXAS
Sector
Primary listing
Employees
6,950
Headquarters
Website
Exact Sciences Metrics
BasicAdvanced
$19B
-
-$5.26
1.47
-
Price and volume
Market cap
$19B
Beta
1.47
52-week high
$101.87
52-week low
$38.81
Average daily volume
7M
Financial strength
Current ratio
2.723
Quick ratio
2.295
Long term debt to equity
99.836
Total debt to equity
101.345
Interest coverage (TTM)
-3.82%
Profitability
EBITDA (TTM)
107.979
Gross margin (TTM)
69.42%
Net profit margin (TTM)
-32.01%
Operating margin (TTM)
-3.58%
Effective tax rate (TTM)
0.82%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-1.09%
Return on equity (TTM)
-34.54%
Valuation
Price to revenue (TTM)
6.175
Price to book
7.68
Price to tangible book (TTM)
-23.79
Price to free cash flow (TTM)
77.019
Free cash flow yield (TTM)
1.30%
Free cash flow per share (TTM)
1.317
Growth
Revenue change (TTM)
14.47%
Earnings per share change (TTM)
350.41%
3-year revenue growth (CAGR)
15.41%
10-year revenue growth (CAGR)
60.89%
3-year earnings per share growth (CAGR)
8.74%
10-year earnings per share growth (CAGR)
12.07%
What the Analysts think about Exact Sciences
Analyst ratings (Buy, Hold, Sell) for Exact Sciences stock.
Exact Sciences Financial Performance
Revenues and expenses
Exact Sciences Earnings Performance
Company profitability
Exact Sciences News
AllArticlesVideos
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium
Business Wire4 days ago
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
Business Wire7 days ago
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday
Investopedia1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Exact Sciences stock?
Exact Sciences (EXAS) has a market cap of $19B as of November 28, 2025.
What is the P/E ratio for Exact Sciences stock?
The price to earnings (P/E) ratio for Exact Sciences (EXAS) stock is 0 as of November 28, 2025.
Does Exact Sciences stock pay dividends?
No, Exact Sciences (EXAS) stock does not pay dividends to its shareholders as of November 28, 2025.
When is the next Exact Sciences dividend payment date?
Exact Sciences (EXAS) stock does not pay dividends to its shareholders.
What is the beta indicator for Exact Sciences?
Exact Sciences (EXAS) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.